Aprea Therapeutics Stock Is Trading Higher As Eprenetapopt Triplet Therapy Achieves 37% CR Rate In Leukemia Patients

  • Aprea Therapeutics Inc APRE has announced that the Phase 1/2 trial evaluating eprenetapopt in acute myeloid leukemia (AML) has met the pre-specified primary efficacy endpoint of complete remission (CR) rate.
  • The trial is assessing eprenetapopt with venetoclax and azacitidine in patients with TP53 mutant AML.
  • In 30 patients who were evaluable for efficacy at the time of the analysis, the CR rate was 37%.
  • The composite rate of CR plus CR with incomplete hematologic recovery (CRi), CR/CRi, was 53%.
  • Eleven patients remain on study treatment and continue to be followed for safety and efficacy as of the data cut.
  • The Company plans to discuss the dataset with the FDA in the second half of 2021.
  • Data from the trial will be presented at a future scientific or medical conference.
  • Price Action: APRE shares are up 49.7% at $7.26 during the premarket session on the last check Wednesday.
Loading...
Loading...
APRE Logo
APREAprea Therapeutics Inc
$1.793.47%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
7.80
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...